Valbiotis Introduces Cholesterol Management Alternative Amid Regulatory Changes

Valbiotis has announced a new product, Lipidrive®, designed as an alternative to red yeast rice for cholesterol management. This comes in response to the European Food Safety Authority's concerns over the safety of monacolins in red yeast rice, which could lead to stricter regulations or a complete ban by June 2026. Lipidrive®, an active component of Valbiotis®PRO Cholesterol, is scientifically validated and free from red yeast rice.

The global market for red yeast rice, valued at $3.3 billion by 2031, is under scrutiny due to associated health risks, including muscle, kidney, and liver damage. In the US, the FDA has already banned it as a dietary supplement. Valbiotis aims to provide a safe, regulation-compliant alternative for health professionals and consumers. The company plans to submit an official health claim application to European authorities later in 2025 to ensure transparency and efficacy in its products.